ATRC

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Atricure Inc

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator ® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
CEO
Employees
750
Headquarters

News

Chief Legal Officer Karl Dahlquist Sells 8,231 Shares of AtriCure Inc (ATRC)
Mar 07, 2024 14:01pm

Chief Legal Officer Karl Dahlquist Sells 8,231 Shares of AtriCure Inc (ATRC)


Source:GuruFocus
AtriCure (ATRC) Fell on Competitor Action
Feb 28, 2024 05:47am

Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fourth quarter witnessed a significant easing in financial conditions, which was most notable in the final two months. Class A shares of the fund outperformed the Russell […]


Source:Insider Monkey
Coinbase To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Friday
Feb 16, 2024 13:30pm

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Piper Sandler raised the price target for Toast, Inc. (NYSE: TOST ) from $18 to $20. Piper Sandler analyst Clarke Jeffries maintained a Neutral rating. Toast shares fell 4.7% to close at $19.20 on Thursday. See how other analysts view this stock . Canaccord Genuity boosted Coinbase Global, Inc. (NASDAQ: COIN ) price target from $140 to $240. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Coinbase shares gained 3.3% to close at $165.67 on Thursday. See how other analysts view this stock. Needham boosted the price target for AtriCure, Inc. (NASDAQ: ATRC ) from $44 to $46. Needham analyst Mike Matson maintained a Buy rating. AtriCure shares rose 5.1% to close at $34.21 on … Full story available on Benzinga.com


Source:Benzinga
Earnings call: AtriCure reports robust growth, eyes new product launches
Feb 16, 2024 12:54pm

https://www.investing.com/news/stock-market-news/earnings-call-atricure-reports-robust-growth-eyes-new-product-launches-93CH-3306283


Source:Investing.com
AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript
Feb 16, 2024 03:30am

No summary available.


Source:Seeking Alpha
AtriCure Non-GAAP EPS of -$0.21 beats by $0.02, revenue of $106.5M beats by $2.34M
Feb 15, 2024 21:07pm

No summary available.


Source:Seeking Alpha
AtriCure''s Earnings: A Preview
Feb 14, 2024 15:01pm

AtriCure (NASDAQ: ATRC ) is set to give its latest quarterly earnings report on Thursday, 2024-02-15. Here''s what investors need to know before the announcement. Analysts estimate that AtriCure will report an earnings per share (EPS) of $-0.23. AtriCure bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com


Source:Benzinga